New product launches to help India's Cipla weather gRevlimid sales void, analysts say

Cipla

24/07/2026 08:26

** Brokerages believe new product launches planned by Indian drugmaker Cipla CIPL.NS will help firm weather near-term challenges from sales void of gRevlimid, Lanreotide
** Launches to drive future growth, improve co's margin trajectory - Dolat Capital says; upgrades to "accumulate" from "reduce", raises TP to 1,600 rupees from 1,387 rupees
** Branded prescription business expected to maintain momentum, aided by growth in acute, chronic portfolios--BOBCaps; keeps "hold", raises PT by 4% to 1,452 rupees
** Shares of Cipla up 2.15% at 1,423 rupees; stock fell 3.4% over a three-day window leading up to Q1 results
** Co reported on Thursday a 39.2% fall in Q1 consolidated net profit to 7.89 billion rupees ($81.7 million), sharply below analysts' estimates of 8.17 billion rupees--LSEG-compiled data
** YTD, CIPL down 6.1% vs pharma index's .NIPHARM 12.5% climb and Nifty 50's .NSEI ~9% drop

($1 = 96.5325 Indian rupees)


 (Reporting by Saikeerthi in Bengaluru)
 ((Saikeerthi@thomsonreuters.com; (+91) 8296756080))